Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines

Identifieur interne : 006496 ( Main/Exploration ); précédent : 006495; suivant : 006497

A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines

Auteurs : Ira M. Longini Jr [États-Unis] ; Michael G. Hudgens [États-Unis] ; M. Elizabeth Halloran [États-Unis] ; Karen Sagatelian [États-Unis]

Source :

RBID : ISTEX:1E3CD170E526B145684C7853F2A4FB51B90088A0

Abstract

We use a discrete‐time non‐homogeneous Markov chain to model data from augmented human immunodeficiency virus (HIV) vaccine trials. For this design, the study population consists of primary participants some of whom have steady sexual partners who are also enrolled to augment the trial. The state space consists of the infection status of primary participants without steady partners and the infection status of both persons in the steady partnerships. The transition probabilities are functions of the two parameters: vaccine efficacy for susceptibility (VES) and infectiousness (VEI). We use likelihood methods to estimate VES and VEI from time‐to‐event data. We then use stochastic simulations to explore the bias and precision of the estimators under various plausible conditions for HIV vaccine trials. We show that both the VES and VEI are estimable with reasonable precision for the conditions that may exist for planned HIV vaccine trials. We show that exams conducted every six months will likely provide sufficient information to estimate the VE parameters accurately, and that there is little gain in precision for more frequent exams. Finally, we show that joint estimation of the VES and VEI will likely be feasible in a currently planned HIV vaccine trial among injecting drug users in Bangkok, Thailand, if one augments the information about the primary participants in the trial with information about their steady sexual partners. Copyright © 1999 John Wiley & Sons Ltd.

Url:
DOI: 10.1002/(SICI)1097-0258(19990115)18:1<53::AID-SIM996>3.0.CO;2-0


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines</title>
<author>
<name sortKey="Longini Jr, Ira M" sort="Longini Jr, Ira M" uniqKey="Longini Jr I" first="Ira M." last="Longini Jr">Ira M. Longini Jr</name>
</author>
<author>
<name sortKey="Hudgens, Michael G" sort="Hudgens, Michael G" uniqKey="Hudgens M" first="Michael G." last="Hudgens">Michael G. Hudgens</name>
</author>
<author>
<name sortKey="Halloran, M Elizabeth" sort="Halloran, M Elizabeth" uniqKey="Halloran M" first="M. Elizabeth" last="Halloran">M. Elizabeth Halloran</name>
</author>
<author>
<name sortKey="Sagatelian, Karen" sort="Sagatelian, Karen" uniqKey="Sagatelian K" first="Karen" last="Sagatelian">Karen Sagatelian</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1E3CD170E526B145684C7853F2A4FB51B90088A0</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1002/(SICI)1097-0258(19990115)18:1<53::AID-SIM996>3.0.CO;2-0</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-LR8FMNX5-Z/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001804</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001804</idno>
<idno type="wicri:Area/Istex/Curation">001804</idno>
<idno type="wicri:Area/Istex/Checkpoint">002401</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002401</idno>
<idno type="wicri:doubleKey">0277-6715:1999:Longini Jr I:a:markov:model</idno>
<idno type="wicri:Area/Main/Merge">006A11</idno>
<idno type="wicri:Area/Main/Curation">006496</idno>
<idno type="wicri:Area/Main/Exploration">006496</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines</title>
<author>
<name sortKey="Longini Jr, Ira M" sort="Longini Jr, Ira M" uniqKey="Longini Jr I" first="Ira M." last="Longini Jr">Ira M. Longini Jr</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA 30322</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Correspondence address: Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA 30322</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hudgens, Michael G" sort="Hudgens, Michael G" uniqKey="Hudgens M" first="Michael G." last="Hudgens">Michael G. Hudgens</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA 30322</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Halloran, M Elizabeth" sort="Halloran, M Elizabeth" uniqKey="Halloran M" first="M. Elizabeth" last="Halloran">M. Elizabeth Halloran</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA 30322</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Sagatelian, Karen" sort="Sagatelian, Karen" uniqKey="Sagatelian K" first="Karen" last="Sagatelian">Karen Sagatelian</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA 30322</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Statistics in Medicine</title>
<title level="j" type="alt">STATISTICS IN MEDICINE</title>
<idno type="ISSN">0277-6715</idno>
<idno type="eISSN">1097-0258</idno>
<imprint>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="53">53</biblScope>
<biblScope unit="page" to="68">68</biblScope>
<biblScope unit="page-count">16</biblScope>
<publisher>John Wiley & Sons, Ltd.</publisher>
<pubPlace>Chichester, UK</pubPlace>
<date type="published" when="1999-01-15">1999-01-15</date>
</imprint>
<idno type="ISSN">0277-6715</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0277-6715</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We use a discrete‐time non‐homogeneous Markov chain to model data from augmented human immunodeficiency virus (HIV) vaccine trials. For this design, the study population consists of primary participants some of whom have steady sexual partners who are also enrolled to augment the trial. The state space consists of the infection status of primary participants without steady partners and the infection status of both persons in the steady partnerships. The transition probabilities are functions of the two parameters: vaccine efficacy for susceptibility (VES) and infectiousness (VEI). We use likelihood methods to estimate VES and VEI from time‐to‐event data. We then use stochastic simulations to explore the bias and precision of the estimators under various plausible conditions for HIV vaccine trials. We show that both the VES and VEI are estimable with reasonable precision for the conditions that may exist for planned HIV vaccine trials. We show that exams conducted every six months will likely provide sufficient information to estimate the VE parameters accurately, and that there is little gain in precision for more frequent exams. Finally, we show that joint estimation of the VES and VEI will likely be feasible in a currently planned HIV vaccine trial among injecting drug users in Bangkok, Thailand, if one augments the information about the primary participants in the trial with information about their steady sexual partners. Copyright © 1999 John Wiley & Sons Ltd.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Géorgie (États-Unis)</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Géorgie (États-Unis)">
<name sortKey="Longini Jr, Ira M" sort="Longini Jr, Ira M" uniqKey="Longini Jr I" first="Ira M." last="Longini Jr">Ira M. Longini Jr</name>
</region>
<name sortKey="Halloran, M Elizabeth" sort="Halloran, M Elizabeth" uniqKey="Halloran M" first="M. Elizabeth" last="Halloran">M. Elizabeth Halloran</name>
<name sortKey="Hudgens, Michael G" sort="Hudgens, Michael G" uniqKey="Hudgens M" first="Michael G." last="Hudgens">Michael G. Hudgens</name>
<name sortKey="Longini Jr, Ira M" sort="Longini Jr, Ira M" uniqKey="Longini Jr I" first="Ira M." last="Longini Jr">Ira M. Longini Jr</name>
<name sortKey="Sagatelian, Karen" sort="Sagatelian, Karen" uniqKey="Sagatelian K" first="Karen" last="Sagatelian">Karen Sagatelian</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006496 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006496 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1E3CD170E526B145684C7853F2A4FB51B90088A0
   |texte=   A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021